Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the formation of a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (GI) system and liver. The collaboration aims to leverage the combined expertise of both companies to address unmet medical needs in these therapeutic areas.
Joint Dedication to Discovery and Development
Under the agreement, EA Pharma and TransThera will jointly dedicate research resources to the discovery and development of potential clinical candidates for GI and liver diseases. This partnership signifies a commitment to advancing scientific understanding and improving patient outcomes in the field of inflammatory diseases.
Establishment of a Joint Steering Committee
To ensure the collaboration’s success, the two companies will establish a joint steering committee responsible for coordinating all scientific matters related to the partnership. This committee will provide oversight and guidance, ensuring that the research and development efforts are aligned with the strategic goals of both organizations.
EA Pharma’s Background and Focus
EA Pharma, established by integrating the gastrointestinal disease business of the Eisai Group and the amino acid technology expertise of the Ajinomoto Group, is a gastrointestinal specialty pharmaceutical company with a full value chain, including research and development, production and logistics, and sales and marketing. The company is focused on the discovery and clinical development of treatments for inflammatory bowel disease (IBD) and a wide range of other gastrointestinal diseases, aiming to provide solutions to unmet clinical needs.
TransThera Sciences’ Commitment to Innovation
TransThera Sciences (Nanjing), Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs. The company operates through an internal research platform and open innovation, with a current portfolio covering therapeutic areas such as oncology, inflammation, and cardiovascular diseases.-Fineline Info & Tech
